Karuna Could Submit Schizophrenia Drug to FDA by Mid-Year

March 20, 2023 by Dan McCue
Karuna Could Submit Schizophrenia Drug to FDA by Mid-Year
Bill Meury, president and chief executive officer, Karuna Therapeutics. (Karuna Therapeutics photo)

BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia, Karuna Therapeutics announced Monday that it is on track to submit KarXT to the Food and Drug Administration for approval by summer.

If that comes to pass, the drug treatment could launch for the treatment of patients in the second half of 2024, the company said in a press release.

Karuna Therapeutics, a clinical-stage biopharmaceutical company, said KarXT met its primary endpoint during a recent phase 3 EMERGENT-3 trial demonstrating a statistically significant and clinically meaningful 8.4-point reduction in Positive and Negative Syndrome Scale total score compared to placebo (-20.6 KarXT vs. -12.2 placebo; P < .0001) at week five (Cohen’s d effect size of 0.60). 

Consistent with prior trials, KarXT also demonstrated an early and sustained statistically significant reduction of symptoms from week two (P < .05) through the end of the trial as assessed by PANSS total score.

“KarXT has now demonstrated a robust and consistent reduction of symptoms across all three registrational trials, providing a compelling picture of the potential of KarXT in schizophrenia,” said Bill Meury, the company’s president and chief executive officer, in a written statement.

“With these data, we are one step closer to a potential treatment option that could provide the first new mechanism of action to treat schizophrenia in several decades,” he added.

Schizophrenia is a serious mental illness characterized by an individual experiencing thoughts or experiences that seem out of touch with reality, disorganized speech or behavior, and decreased participation in daily activities. 

Treatment is usually lifelong and often involves a combination of medications, psychotherapy and coordinated specialty care services.

“Despite the number of currently available treatments, there remains a significant need for new treatment options for the 21 million people living worldwide with schizophrenia,” said David Walling, Ph.D., chief clinical officer at CenExel-CNS and investigator on the EMERGENT-3 trial. 

“The results from the EMERGENT-3 trial add to the growing body of data which suggest KarXT could address the symptoms of schizophrenia without the common side effects we see with current treatment options,” Walling said.

Karuna said its new drug application for KarXT in schizophrenia will incorporate the efficacy and safety data from the three placebo-controlled registrational trials, EMERGENT-1, EMERGENT-2 and EMERGENT-3, in addition to long-term safety data from the ongoing EMERGENT-4 and EMERGENT-5 trials.

Dan can be reached at [email protected] and @DanMcCue

A+
a-
  • FDA
  • Food and Drug Administration
  • Karuna Therapeutics
  • KarXT
  • Schizophrenia
  • In The News

    Health

    Voting

    Business

    March 28, 2024
    by Dan McCue
    Silicon Valley-Based Firm Launches ‘Radar as a Service’

    BELMONT, Calif. — At first the idea sounds about as un-Silicon Valley as one can get. After all, the basic... Read More

    BELMONT, Calif. — At first the idea sounds about as un-Silicon Valley as one can get. After all, the basic concept underlying radar was proven in 1886, when a German physicist named Heinrich Hertz showed that radio waves could be reflected from solid objects. And the... Read More

    March 28, 2024
    by Tom Ramstack
    Disney World Settles with Florida After Its Opposition to 'Don’t Say Gay' Law

    ORLANDO — The company that runs Walt Disney World reached a settlement Wednesday with appointees of Florida Gov. Ron DeSantis... Read More

    ORLANDO — The company that runs Walt Disney World reached a settlement Wednesday with appointees of Florida Gov. Ron DeSantis who were exerting controversial regulatory control over the huge tourism complex. The settlement resolves some of the disputes that arose after Disney officials publicly denounced the... Read More

    March 26, 2024
    by Dan McCue
    Sen. Blumenthal Lauds Expansion of Tax Credit for Offshore Wind Projects

    NEW LONDON, Conn. — Sen. Richard Blumenthal, D-Conn., visited State Pier in New London, Connecticut, on Monday to tout and... Read More

    NEW LONDON, Conn. — Sen. Richard Blumenthal, D-Conn., visited State Pier in New London, Connecticut, on Monday to tout and celebrate the Biden administration’s decision to expand eligibility of federal tax credits for offshore wind projects. “This tax credit has been a long time in coming,”... Read More

    March 25, 2024
    by Dan McCue
    Energy Department Awards $6B to Decarbonization Projects

    WASHINGTON — The U.S. Department of Energy on Monday awarded $6 billion to 33 projects across more than 20 states... Read More

    WASHINGTON — The U.S. Department of Energy on Monday awarded $6 billion to 33 projects across more than 20 states to decarbonize energy-intensive industries while creating jobs and revitalizing the communities in which they are located. Funded by the bipartisan infrastructure law and Inflation Reduction Act,... Read More

    Energy Agency Announces $6B to Slash Emissions in Industrial Facilities

    The Biden administration announced $6 billion in funding Monday for projects that will slash emissions from the industrial sector —... Read More

    The Biden administration announced $6 billion in funding Monday for projects that will slash emissions from the industrial sector — the largest-ever U.S. investment to decarbonize domestic industry to fight climate change. The industrial sector is responsible for roughly 25% of all the nation’s emissions, and has... Read More

    Trump's Social Media Company Will Go Public After Merger With Shell Company Approved

    NEW YORK (AP) — Donald Trump is returning to the stock market. Shareholders of Digital World Acquisition Corp., a publicly... Read More

    NEW YORK (AP) — Donald Trump is returning to the stock market. Shareholders of Digital World Acquisition Corp., a publicly traded shell company, approved a deal to merge with the former president’s media business in a Friday vote. That means Trump Media & Technology Group, whose... Read More

    News From The Well
    scroll top